Press Releases

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates to treat patients with neurological and psychiatric disease.

July 24, 2017

AgeneBio Founder Presents at Alzheimer’s Association International Conference

Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.”   Details available here.

February 17, 2016

AgeneBio to Present at Neuroscience BioPartnering & Investment Forum

Baltimore, MD, February 17, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at the Neuroscience BioPartnering & Investment Forum. CEO Jerry McLaughlin will present a overview of AgeneBio‘s work in…

February 2, 2016

AgeneBio to Present at BIO CEO & Investor Conference

Baltimore, MD, February 2, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at BIO CEO & Investor Conference. CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at…

December 15, 2015

AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website

Trial to Study AGB101 to Determine if it Can Slow Progression of Symptoms Associated with aMCI and Prevent or Delay Onset of Alzheimer’s Dementia Baltimore, MD, December 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling…

December 8, 2015

AgeneBio Appoints Richard Mohs, PhD, Vice President of Clinical Development

Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug…

November 24, 2015

AgeneBio to Present at Future of Innovation in Medicine Conference

Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical…